Justice Kavanaugh voted to grant Teva’s petition for certiorari. It is unknown if other justices voted with him. The high court last month declined to hear Novartis's Gilenya patent case and Sanofi’s antitrust allegations against Mylan’s EpiPen rebate agreements.

Agency refutes Supernus’ defense that Sage’s generic drug cartridges are ‘free-riding’ on the supply of the injector pen for its branded product. Company’s alleged exclusionary contract with pen distributor and pressure on specialty pharmacies not to provide the generic involve important antitrust issues, FTC tells court.

Scrip looks at the contours of MPP’s recent sub-licensing deal for ViiV Healthcare’s cabotegravir with Cipla, Aurobindo and Mylan, along with pricing dynamics and precedents to evaluate a few barriers to access

US Solicitor General urges the Supreme Court to grant Teva's petition, arguing that the Federal Circuit was wrong in ruling that Teva's carved-out labeling for generic carvedilol induced infringement of GlaxoSmithKine's brand product.